Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver
- 10 August 2014
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 21 (2) , 379-387
Abstract
Hepatocellular carcinoma (HCC) remains a common malignant cancer worldwide, it is considered the fifth most common malignant cancer. On the other hand, metastatic tumors are widespread in the liver , with metastatic adenocarcinoma (MA) constituting the greatest part, therefore differentiation of HCC from MA is a frequent problem facing the pathologist especially in liver fine-needle aspiration biopsies. Evaluating the diagnostic value of glypican-3 (GPC-3) and HepPar-1 immunostaining in differentiating hepatocellular carcinoma from metastatic tumors in liver cell block material. Fourty eight cell blocks prepared from FNA from the liver ( 30 cases HCC, 18 cases metastatic carcinoma in liver ) stained by Glypican -3 and HepPar-1 immunohistochemical markers. Glypican-3 was immunoexpressed in 97 % of cases of HCC while all cases of metastatic carcinoma were negative . HepPar-1 was expressed in 93 % of cases of HCC and 11 % of metastatic carcinoma of the liver . In this study the sensitivity of GPC3 in the diagnosis of HCC in cytological material was 96.7% and the specificity was 100% while the sensitivity and specificity of HepPar-1 was 93.3 % and 88.9 % respectively. Immunohistochemical staining for GPC-3 in cell block material of the liver is highly sensitive and specific and it is a valuable tool capable of differentiating HCC from most of metastatic tumors of the liver.Keywords
This publication has 27 references indexed in Scilit:
- The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1Diagnostic Pathology, 2012
- Arginase-1, HepPar-1, and Glypican-3 Are the Most Effective Panel of Markers in Distinguishing Hepatocellular Carcinoma From Metastatic Tumor on Fine-Needle Aspiration SpecimensAmerican Journal of Clinical Pathology, 2012
- Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumorsDiagnostic Pathology, 2012
- Hepatocellular Carcinoma: Focus on Different Aspects of ManagementISRN Oncology, 2012
- Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infectionOncology Letters, 2011
- Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosisCytopathology, 2011
- Arginase-1American Journal of Surgical Pathology, 2010
- Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancerInternational Journal of Oncology, 2009
- Value of Glypican 3 Immunostaining in the Diagnosis of Hepatocellular Carcinoma on Needle BiopsyAmerican Journal of Clinical Pathology, 2008
- The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinomaLaboratory Investigation, 2005